Dr. Anthony Leachon told Rappler that the fight against disinformation must be continued in the face of rising dangers of ...

Please don’t say the company is trying to fix healthcare. But it’s melding its pharmacy, in-person, and virtual services into ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024. Topline clinical data from SOL-1 are now expected in Q4 2025. BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWS ...

This research uncovers the complex relationship between blood pressure treatment and mental health, advocating for ...

Early-life rationing reduced diabetes and hypertension risk by about 35% and 20%, respectively, and delayed disease onset by 4 and 2 years. Study: Exposure to sugar rationing in the first 1000 ...

In 2017, the American Heart Association revised the definition of high blood pressure, lowering the threshold to 130/80 mm Hg ...

Researchers have found that, regardless of BP level and age, secondary hypertension is common among young adults with hypertension.

Higher medical expenditures and higher out-of-pocket expenses are associated with hypertension among adults in the United States with private insurance.

A replay of the webcasts will be available on the Company’s website for approximately 90 days. About Mineralys Therapeutics Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused ...

Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally.